Stocklytics Platform
Asset logo for symbol OGN
Organon & Co.
OGN65
$14.62arrow_drop_down1.77%-$0.26
Asset logo for symbol OGN
OGN65

$14.62

arrow_drop_down1.77%

Income Statement (OGN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT$333.00M$366.00M$414.00M$314.00M$167.00M
EBITDA$402.00M$432.00M$479.00M$374.00M$228.00M
gross Profit$923.00M$939.00M$957.00M$915.00M$907.00M
NET Income$359.00M$195.00M$201.00M$546.00M$58.00M
total Revenue$1.58B$1.60B$1.62B$1.59B$1.51B

Balance Sheet (OGN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents----$414.00M
net Debt$7.98B$7.95B$8.13B$8.06B$8.24B
stockholders Equity$493.00M$144.00M$48.00M-$70.00M-$589.00M
total Assets$12.75B$12.15B$11.89B$12.05B$11.01B
total Debt$8.74B$8.65B$8.71B$8.76B$8.65B
total Liabilities$12.25B$12.01B$11.84B$12.12B$11.60B

Cash Flow (OGN)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$78.00M-$134.00M-$74.00M-$77.00M-$78.00M
free Cash Flow$65.00M$285.00M$30.00M$316.00M$206.00M
investing Cash Flow-----$179.00M
operating Cash Flow$141.00M$332.00M$76.00M$397.00M$261.00M

Organon & Co. (OGN) Financials

Organon & Co. (OGN) is a pharmaceutical company that focuses on improving the health and well-being of people around the world. The company is committed to developing innovative solutions that address the unmet needs of patients and healthcare providers. Organon & Co. (OGN) prides itself on its strong financial performance and its ability to generate sustainable growth. The company's income statement reflects its revenue and expenses over a specific period of time. It provides a snapshot of the company's profitability. Organon & Co. (OGN) also reports its EBIT (Earnings Before Interest and Taxes), which measures its operating income before deducting interest and taxes. This metric helps to gauge the company's profitability from its core operations.
Additionally, Organon & Co. (OGN) reports its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which provides a clearer picture of the company's operating performance by excluding non-cash expenses. This metric is often used to evaluate a company's cash-generating ability. The company's gross profit represents the revenue remaining after deducting the cost of goods sold. Organon & Co. (OGN) strives to maintain a healthy gross profit margin, which indicates the efficiency of its operations. It is important for the company to generate sufficient gross profit to cover its operating expenses and have a net income for stockholders.
Organon & Co. (OGN) reports its net income from stockholders, which represents the profit available to shareholders after all expenses and taxes have been paid. This metric helps investors evaluate the company's profitability and ability to reward its stockholders. The company's total revenue reflects the sum of its sales from products and services. Organon & Co. (OGN) aims to grow its total revenue by introducing new products and expanding its market share.
Turning to the balance sheet, Organon & Co. (OGN) reports its financial position at a specific point in time. The balance sheet includes its assets, liabilities, and stockholders' equity. The company's cash equivalents represent highly liquid assets that can be easily converted into cash. Organon & Co. (OGN) monitors its cash equivalents to ensure it has sufficient liquidity to meet its financial obligations.
The company's net debt is the difference between its total debt and its cash equivalents. Organon & Co. (OGN) strives to manage its net debt effectively to maintain a healthy financial position. Stockholders' equity represents the residual interest in the assets of the company after deducting its liabilities. It indicates the company's net worth and financial stability. Organon & Co. (OGN) focuses on increasing its stockholders' equity to enhance its financial strength.
Organon & Co. (OGN) also reports its total assets, which include its cash, investments, property, and other resources. The company's total debt reflects its obligations to repay borrowed funds. Organon & Co. (OGN) carefully manages its total debt to ensure it remains within manageable levels. The total liabilities represent the company's financial obligations to creditors and other stakeholders.
In terms of cash flow, Organon & Co. (OGN) reports its operating cash flow, which represents the cash generated from its core operations. This metric helps evaluate the company's ability to generate cash from its day-to-day activities. The company's financing cash flow reflects the cash flow from activities related to its financing, such as equity issuances, debt repayments, and dividend payments.
Organon & Co. (OGN) also reports its free cash flow, which represents the cash available for reinvestment or distribution to stockholders after deducting capital expenditures. This metric is important for investors as it indicates the company's financial flexibility and potential for future growth. The company's investing cash flow reflects the cash flow from activities related to its investments, such as acquisitions, purchases of property, plant, and equipment, and proceeds from the sale of investments.
Overall, Organon & Co. (OGN) places a strong emphasis on its financial performance and transparency. The company's financial statements provide valuable insights into its profitability, liquidity, and financial stability. Organon & Co. (OGN) remains committed to delivering sustainable growth and creating long-term value for its shareholders while advancing the health and well-being of individuals worldwide.
add Organon & Co. to watchlist

Keep an eye on Organon & Co.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level